Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to ...

AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, ...

BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. On September 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced new findings from its Phase 2 ...

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. ImmunityBio, Inc. is one of them.

A new review highlights sepsis-induced immunosuppression as a key driver of mortality, summarizing current research and ...

In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, ...

Shiong’s portfolio saw a slight drop over past 12 months as the value of his stake in Culver City immunotherapy firm ...

A new study finds that EULAR/ACR criteria identify more systemic lupus erythematosus cases among patients with interstitial ...

A simultaneous or sequential combination of brentuximab vedotin and radiotherapy is feasible and well tolerated in patients ...

The nonoperative regimen led to a 2-year total mesorectal excision (TME)-free survival of 57% in 63 evaluable patients, and a ...